Schroder Investment Management Group Has $961,000 Stock Holdings in STAAR Surgical (NASDAQ:STAA)

Posted by on Jun 4th, 2023

Schroder Investment Management Group increased its holdings in shares of STAAR Surgical (NASDAQ:STAA – Get Rating) by 47.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,803 shares of the medical instruments supplier’s stock after buying an additional 6,411 shares during the period. Schroder Investment Management Group’s holdings in STAAR Surgical were worth $961,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in STAA. MCF Advisors LLC bought a new position in STAAR Surgical during the 3rd quarter worth approximately $40,000. Assetmark Inc. raised its holdings in STAAR Surgical by 42.1% during the 4th quarter. Assetmark Inc. now owns 645 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 191 shares during the last quarter. Lazard Asset Management LLC raised its holdings in STAAR Surgical by 131.1% during the 1st quarter. Lazard Asset Management LLC now owns 684 shares of the medical instruments supplier’s stock worth $54,000 after purchasing an additional 388 shares during the last quarter. UBS Group AG raised its holdings in STAAR Surgical by 130.7% during the 2nd quarter. UBS Group AG now owns 805 shares of the medical instruments supplier’s stock worth $57,000 after purchasing an additional 456 shares during the last quarter. Finally, Captrust Financial Advisors raised its holdings in STAAR Surgical by 348.4% during the 2nd quarter. Captrust Financial Advisors now owns 825 shares of the medical instruments supplier’s stock worth $59,000 after purchasing an additional 641 shares during the last quarter. 97.55% of the stock is currently owned by institutional investors and hedge funds.

STAAR Surgical Trading Down 0.1 %

Shares of STAA stock opened at $57.70 on Friday. The firm has a market capitalization of $2.79 billion, a PE ratio of 90.16 and a beta of 1.18. The firm has a fifty day simple moving average of $64.47 and a two-hundred day simple moving average of $63.02. STAAR Surgical has a 12 month low of $46.35 and a 12 month high of $112.27.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on STAA shares. Needham & Company LLC raised their price target on shares of STAAR Surgical from $78.00 to $84.00 in a report on Thursday, May 4th. Piper Sandler initiated coverage on shares of STAAR Surgical in a research note on Monday, April 17th. They issued a “neutral” rating and a $65.00 price objective for the company. StockNews.com initiated coverage on shares of STAAR Surgical in a research note on Thursday, May 18th. They issued a “hold” rating for the company. BTIG Research lowered shares of STAAR Surgical from a “buy” rating to a “neutral” rating in a research note on Monday, February 6th. Finally, Stephens reiterated an “overweight” rating and issued a $85.00 price objective on shares of STAAR Surgical in a research note on Wednesday, February 22nd. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $81.18.

Insider Buying and Selling at STAAR Surgical

In other STAAR Surgical news, CTO Keith Holliday sold 823 shares of the business’s stock in a transaction on Friday, March 17th. The shares were sold at an average price of $61.97, for a total transaction of $51,001.31. Following the completion of the sale, the chief technology officer now owns 27,633 shares in the company, valued at approximately $1,712,417.01. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.10% of the stock is currently owned by company insiders.

STAAR Surgical Profile

(Get Rating)

STAAR Surgical Co engages in the development, manufacture, production, marketing, and sale of implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It specializes in refractive and cataract solutions. Its products include intraocular lens and implantable collamer lens.

Featured Articles

Want to see what other hedge funds are holding STAA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STAAR Surgical (NASDAQ:STAA – Get Rating).

Institutional Ownership by Quarter for STAAR Surgical (NASDAQ:STAA)

Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.